GLP-1 Receptor Agonist Side Effects: What Studies Report

Evidence tier: Established. GLP-1 receptor agonists are approved prescription medicines that were studied in large randomised phase 3 programmes and, more recently, in large real-world cohorts, so the adverse-event profile described below is drawn from published trial reports and peer-reviewed reviews rather than from preliminary or unpublished work.

The phrase "GLP-1 side effects" is used in two quite different ways. In almost all clinical usage it refers to the medicine class: semaglutide, tirzepatide (a dual GIP and GLP-1 receptor agonist), liraglutide and related agents. Much less often it refers to the endogenous hormone glucagon-like peptide-1 itself, which the body releases after eating. This page summarises what published studies reported about the medicines, and separates drug effects from hormone physiology in a dedicated section below. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, symptom or treatment decision.

What the class shares: a mechanism-driven side-effect pattern

Because these agents act on the same receptor family and slow gastric emptying while altering appetite signalling, the adverse events reported across programmes cluster in the digestive tract. A 2025 review of GLP-1 receptor agonists in obesity treatment framed tolerability and the practical obstacles to long-term use as central issues alongside the efficacy data (PMID 41333115). A comparative narrative review of semaglutide, liraglutide and tirzepatide examined cardiometabolic outcomes across the three agents and noted that they differ in potency and receptor targets while sharing a broadly similar tolerability theme (PMID 42747132).

Gastrointestinal Events: What Studies Report

Gastrointestinal adverse events are the most consistently reported finding in this drug class. An analysis of the SURPASS clinical trials examined gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide, and the researchers reported that nausea, vomiting and diarrhoea were common, generally mild to moderate, and concentrated around periods of dose escalation (PMID 37853960). That same analysis explored whether gastrointestinal events accounted for the weight reduction observed, reporting that weight loss occurred in participants both with and without such events (PMID 37853960).

A 2025 comparative safety paper on semaglutide and tirzepatide summarised side-effect data for both agents and discussed the implications for clinical decision-making in obesity management, with gastrointestinal intolerance the dominant reported category (PMID 41177120). Reviews of semaglutide in obesity management similarly reported gastrointestinal complaints as the most frequent treatment-emergent events across the clinical programme (PMID 35958046).

Why escalation matters in the trial record

Trial protocols in this class used stepwise dose increases, and the SURPASS gastrointestinal analysis reported that event rates were highest during escalation intervals rather than at steady maintenance exposure (PMID 37853960). In the oral semaglutide programme, PIONEER 7 tested a flexible dose-adjustment approach using 3 mg, 7 mg and 14 mg tablets versus sitagliptin in type 2 diabetes, and the study reported efficacy and safety outcomes for that individualised adjustment strategy (PMID 31189520). Nothing here describes what any individual should do; it describes how the trials were structured.

Per-drug differences reported in the literature

Gallbladder, Pancreas and Less Common Signals: What Studies Report

Beyond routine gastrointestinal complaints, reviews of the class have discussed a smaller set of signals that attract regulatory and clinical attention. The 2025 comparative safety review of semaglutide and tirzepatide addressed these less frequent safety topics — including pancreatic and biliary events — as part of its framework for clinical decision-making in obesity management (PMID 41177120). A 2025 review of GLP-1 receptor agonists for obesity treatment likewise catalogued safety concerns among the "obstacles on the horizon" that researchers considered unresolved for long-term use (PMID 41333115). Real-world evidence work on newer GLP-1 receptor agonist-based weight-loss therapies examined adverse effects outside the controlled trial setting, where populations are less selected than in phase 3 programmes (PMID 40196933).

Body composition and the muscle-mass discussion

The question of how much of the weight reduction is fat versus lean tissue is an active discussion in this literature rather than a settled adverse-event finding. A 2025 review of GLP-1 receptor agonists for obesity treatment placed body-composition and durability questions among the prospects and obstacles researchers identified for the class (PMID 41333115), and reviews of semaglutide in obesity management have summarised the magnitude of weight reduction reported across the clinical programme alongside its tolerability profile (PMID 35958046).

Hair shedding: What Studies Report

A systematic review of GLP-1 therapies and hair loss assessed the current evidence base and its implications for patient counselling, reporting that the available data were limited and that counselling considerations were the review's main practical focus (PMID 41998799). Rapid weight reduction itself is a long-recognised trigger discussed in that literature, which is why the review framed the topic as one requiring careful interpretation rather than a confirmed drug-specific effect (PMID 41998799).

Special populations and pharmacokinetics

Tolerability in specific populations has been examined in dedicated pharmacology studies. Researchers assessed the pharmacokinetics and tolerability of a single dose of semaglutide in subjects with and without renal impairment, reporting exposure and tolerability data across renal-function groups (PMID 28349386). Studies of this kind inform prescribing labels; they are not guidance for any individual.

Discontinuation: What Studies Report

Stopping treatment is one of the most-studied practical outcomes in this class. A 2025 review of real-world evidence examined the utilisation, clinical and comparative effectiveness, and adverse effects of newer GLP-1 receptor agonist-based weight-loss therapies, reporting that patterns of use and persistence outside trials differ from those observed in randomised programmes (PMID 40196933). In the randomised setting, the SURPASS gastrointestinal analysis reported that treatment discontinuation due to gastrointestinal adverse events occurred in a minority of tirzepatide-treated participants relative to the number who experienced such events at all (PMID 37853960). The 2025 comparative safety review of semaglutide and tirzepatide discussed how tolerability influences persistence with therapy in obesity management (PMID 41177120).

Hormone physiology versus drug effect

This distinction matters because the two are often conflated. Endogenous GLP-1 is an incretin hormone secreted by intestinal L-cells after a meal; it is degraded within minutes and acts at physiological concentrations. Background on that biology sits on the GLP-1 physiology page. GLP-1 receptor agonist medicines are engineered to resist that rapid degradation and to hold receptor activation far longer and at higher exposure than meal-driven hormone release. Reviews of semaglutide in metabolic medicine described how this pharmacological profile underpins both the metabolic effects and the tolerability pattern observed in trials (PMID 42237968). Oral semaglutide reviews described the additional formulation step required for absorption of a peptide taken as a tablet (PMID 37312901), and comparative analyses of oral semaglutide in type 2 diabetes summarised how the route affects clinical positioning (PMID 34468297). In short: the adverse events discussed on this page are attributes of sustained pharmacological receptor agonism, not descriptions of ordinary post-meal hormone physiology.

How to read adverse-event reporting in these trials

• Frequency is not severity. The SURPASS analysis reported gastrointestinal events as common but predominantly mild to moderate in intensity (PMID 37853960).
• Trial populations are selected. Real-world reviews examined broader, less-screened populations and different persistence patterns (PMID 40196933).
• Head-to-head framing is limited. The comparative safety review of semaglutide and tirzepatide synthesised data across sources rather than from a single randomised safety comparison (PMID 41177120).
• Some questions stay open. A 2025 obesity-treatment review described unresolved obstacles for the class despite its reported efficacy (PMID 41333115).

Related reading

• Semaglutide: what studies report
• Tirzepatide: what studies report
• Semaglutide overview
• Glucagon-like peptide-1 physiology

Regulatory and naming notes

GLP-1 receptor agonists discussed here are prescription medicines approved by regulators for specific indications; approved labelling, not this page, governs their use. Brand names are used only to identify the products referenced in the cited literature, and each brand name is a trademark of its owner. PeptideU is an independent educational publisher and is not affiliated with or endorsed by any pharmaceutical manufacturer, prescriber or clinic. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine or symptom.

References

• Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials (Diabetes, Obesity & Metabolism, 2024)
• Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management (Biomedicine & Pharmacotherapy, 2025)
• Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon (Journal of Obesity, 2025)
• GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling (Science Progress, 2026)
• Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies (Diabetes, Obesity & Metabolism, 2025)
• Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment (Clinical Pharmacokinetics, 2017)
• Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7) (The Lancet Diabetes & Endocrinology, 2019)
• Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis (Current Drug Targets, 2022)
• A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes (Diabetes, Metabolic Syndrome and Obesity, 2023)
• Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review (Clinical Pharmacology: Advances and Applications, 2022)
• Semaglutide in Metabolic Medicine: A Review on Clinical Applications and Emerging Therapeutics (Saudi Medical Journal, 2026)
• Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review (Endocrinology, Diabetes & Metabolism, 2026)